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Abstract
Background/Aims: Myocardial stretch increases cardiac force in two consecutive phases: 
The first one due to Frank-Starling mechanism, followed by the gradually developed slow 
force response (SFR). The latter is the mechanical counterpart of an autocrine/paracrine 
mechanism involving the release of angiotensin II (Ang II) and endothelin (ET) leading to 
Na+/H+ exchanger 1 (NHE-1) phosphorylation and activation. Since previous evidence 
indicates that p38-MAP kinase (p38-MAPK) negatively regulates the Ang II-induced NHE-
1 activation in vascular smooth muscle and the positive inotropic effect of ET in the heart, 
we hypothesized that this kinase might modulate the magnitude of the SFR to stretch. 
Methods: Experiments were performed in isolated rat papillary muscles subjected to sudden 
stretch from 92 to 98% of its maximal length, in the absence or presence of the p38-MAPK 
inhibitor SB202190, or its inactive analogous SB202474. Western blot technique was used 
to determine phosphorylation level of p38-MAPK, ERK1/2, p90RSK and NHE-1 (previously 
immunoprecipitated with NHE-1 polyclonal antibody). Dual specificity phosphatase 6 (DUSP6) 
expression was evaluated by RT-PCR and western blot. Additionally, the Na+-dependent 
intracellular pH recovery from an ammonium prepulse-induced acid load was used to asses 
NHE-1 activity. Results: The SFR was larger under p38-MAPK inhibition (SB202190), effect that 
was not observed in the presence of an inactive analogous (SB202474). Myocardial stretch 
activated p38-MAPK, while pre-treatment with SB202190 precluded this effect. Inhibition 
of p38-MAPK increased stretched-induced NHE-1 phosphorylation and activity, key event 
in the SFR development. Consistently, p38-MAPK inhibition promoted a greater increase in 
ERK1/2-p90RSK phosphorylation/activation after myocardial stretch, effect that may certainly 
be responsible for the observed increase in NHE-1 phosphorylation under this condition. 
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Myocardial stretch induced up-regulation of the DUSP6, which specifically dephosphorylates 
ERK1/2, effect that was blunted by SB202190. Conclusion: Taken together, our data support 
the notion that p38-MAPK activation after myocardial stretch restricts the SFR by limiting 
ERK1/2-p90RSK phosphorylation, and consequently NHE-1 phosphorylation/activity, through 
a mechanism that involves DUSP6 up-regulation.
Introduction
Myocardial stretch is an important physiological stimulus that allows the heart to 
modulate its contractile performance, and consequently adapt cardiac output to changes 
in hemodynamic conditions. It is well known that the stretch of cardiac muscle induces a 
two-phase increase in force: First, the Frank-Starling mechanism attributed to enhanced 
myofilament responsiveness to calcium; followed by the slow force response (SFR), due 
to an increase in the intracellular calcium transient. Previous studies from our laboratory 
provided evidence supporting that the SFR is the mechanical expression of a stretch-triggered 
autocrine/paracrine loop of cell signaling that involves: 1) the sequential activation of 
angiotensin II (Ang II), endothelin (ET) and mineralocorticoid receptors (AT1, ETA and MR 
respectively), 2) transactivation of the epidermal growth factor receptor, 3) reactive oxygen 
species (ROS) production, 5) activation of kinases upstream the cardiac isoform of the Na+/
H+ exchanger (NHE-1), such as ERK1/2 and p90RSK, 6) NHE-1 hyperactivity, 7) increase in 
intracellular Na+ concentration, and 8) increase in Ca2+ transient amplitude through reverse 
Na+/Ca2+ exchange [1]. In the present study we explored the possible participation of p38 
MAP kinase (p38-MAPK) in this intracellular cascade. Previous evidence highlights the 
importance of p38-MAPK activation in the regulation of different cardiovascular processes 
[2-4]. In this sense, even though several reports showed that p38-MAPK negatively regulates 
cardiac function [5-9], the underlying mechanism is not fully understood. It has been shown 
that inhibition of p38-MAPK increases myofilament Ca2+ sensitivity [5], and its activation 
decreases α-tropomyosin phosphorylation and ATPase activity [9]. Interestingly, Szokodi 
et al. [10] working in isolated perfused rat hearts showed that pharmacological inhibition 
of p38-MAPK strengthens the positive inotropic response to ET-1, effect attributed to an 
increased phosphorylation of phospholamban (PLN) at the residue serine 16. On the 
other hand, experiments by Kusuhara et al. [11] in isolated vascular smooth muscles cells 
showed that Ang II promotes not only ERK1/2 but also p38-MAPK activation. Interestingly, 
the authors proposed a crosstalk between these kinases, being p38-MAPK responsible for 
a decrease in ERK1/2 activity that consequently reduces the activation of its downstream 
kinase, p90RSK. Later on, this group showed in the same preparation that p90RSK was 
able to phosphorylate the serine 703 of the NHE-1 stimulating its activity in response to 
Ang II [12]. They coined the term “NHE-1 kinase” to identify the p90RSK [12]. Taken this 
evidence together, and considering that Ang II, ET and the NHE-1 are known mediators of 
the signaling pathway leading to the SFR, we hypothesized that p38-MAPK may conceivably 
participate in this important mechanism. In this work, we will present evidence supporting 
that p38-MAPK activation after myocardial stretch limits the increase in force during the SFR 
by limiting NHE-1 phosphorylation through a mechanism that involves up-regulation of the 
dual specificity phosphatase 6 (DUSP6).
Materials and Methods
All procedures followed during this investigation conform to the Guide for the Care and Use of Laboratory 
Animals (National Research Council. 2011, Eighth Edition. Washington, DC: The National Academies Press) 
[13] and the experimental protocol was approved by the Animal Welfare Committee of La Plata School of 
Medicine.
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Wistar rats (n =36, bodyweight 300-400 g) were anaesthetized by intraperitoneal injection of sodium 
pentobarbital (35 mg/kg body weight). The chests were opened to excise the heart when deep anaesthesia 
was reached, verified by the loss of corneal reflex and appearance of slow deep diaphragmatic breathing. 
Animals were provided by the Animal Facilities of the Centro de Investigaciones Cardiovasculares, “Dr. 
Horacio E. Cingolani”. Each heart was used to provide at least 2 papillary muscles.
Isolation of papillary muscles
Papillary muscles from the left ventricle were used to assess the SFR to stretch as previously described 
[14]. Briefly, the muscles were mounted in a perfusion chamber placed on the stage of an inverted microscope 
(Olympus) and superfused at a constant rate (5ml/min) with a CO2/HCO3−-buffered solution containing 
(mmol/L): NaCl 128.3, KCl 4.5, CaCl2 1.35, NaHCO3 20.23, MgSO4 1.05, glucose 11.0 and equilibrated with 5 
% CO2–95 % O2 (pH ~7.40). The possible participation of catecholamines released by the nerve endings was 
prevented by adrenergic receptors blockade with 1.0 μmol/L prazosin plus 1.0 μmol/L atenolol. The muscles 
were paced at 0.2 Hz at a voltage 10 % over threshold maintained at 30ºC, and isometric contractions were 
recorded. Cross sectional area of each muscle (CSA in mm2: Stretch 0.356±0.026, n=16; Stretch+SB202190 
0.399±0.024, n=21; Stretch+SB202474 0.369±0.051, n=8; NS), which was calculated as 0.75 of the product 
of thickness and width, was used to normalize force records obtained with a silicon strain gauge (model 
AEM 801, Kronex Technologies Corp, Oakland, CA, USA). Immediately after mounting, the slack length of 
each muscle was determined and then the muscles were progressively stretched to the length at which 
they developed maximal twitch force (Lmax). After a few minutes at Lmax, they were shortened to obtain 
the 95 % of the maximal twitch force (length that approximated 98 % of Lmax and referred to as L98). 
Then, the muscles were shortened to 92 % of Lmax (L92) and maintained at this length until the beginning 
of the experimental protocol, when they were abruptly stretched from L92 to L98. p38-MAPK inhibitor, 
SB202190, or its inactive analogous, SB202474, were added to the perfusate 20 min before stretch. Neither 
the p38-MAPK inhibitor, SB202190, nor its inactive analogous, SB202474, induced significant changes in 
basal developed force of papillary muscles (101.9±1.2 % of pre-SB202190, n=21 and 104.2±1.8 % of pre-
SB202474, n=8).
NHE-1 activity
Intracellular pH (pHi) was measured in isolated left ventricular papillary muscles from male Wistar 
rats following a previously described BCECF-epifluorescence technique [15]. The muscles were loaded 
with the ester form of the pH-sensitive fluorescent dye BCECF (Invitrogen, Molecular Probes). The dye was 
solubilized in dimethyl sulfoxide (Sigma Chemical Co) containing pluronic acid F-127 (20 % [wt/vol]) and 
diluted to a final concentration of 10 µmol/L in HCO3-/CO2-buffered solution. After autofluorescence levels 
were recorded, the muscles were incubated for 1 hour in the BCECF-AM containing solution. At the end 
of the loading period, washout of the extracellular space with dye-free solution was carried out for 30-60 
minutes before any pHi determination was done. At this time, BCECF fluorescence was uniformly distributed 
throughout the muscle. To measure fluorescence emission from BCECF, excitation light from a 75-W Xenon 
lamp was band pass-filtered alternatively at 440 and 495 nm and was then transmitted to the muscles under 
study by a dichroic mirror (reflecting wavelengths, pass filter at 535±5 nm to a photomultiplier (model 
R2693, Hamamatsu). The output of the photomultiplier was collected via an A/D converter (model 2801 A, 
Data Translation) and stored in a personal computer for later analysis. To limit photobleaching, a neutral 
density filter (1 % transmittance) was placed in the excitation light path, and a manual shutter was used to 
select sampling intervals (2 seconds every ~10 seconds) during the protocol.
The NHE-1 activity, after sustained acidosis, was assessed by the Na+-dependent pHi recovery from 
an ammonium prepulse-induced acute acid load [15]. The experiments were performed in the nominal 
absence of bicarbonate (HEPES buffer) to assure that the pHi recovery after the acidic load was entirely due 
to NHE-1 activation. The papillary muscles were acid loaded by brief (10 min) exposure to 20.0 mmol/L 
NH4Cl followed by washout with Na+ -free HEPES buffer (NaCl was equimolar replaced with N-methyl-
D-glucamine). Recovery of pHi after acid loading was induced by re-introduction of external Na+ after 10 
minutes of acidosis. The intracellular buffer capacity (βi) was determined as previously described [16]. 
Maximal H+ efflux (JH+= maxdpHi /dt. βi) was calculated at the beginning of recovery from acidosis (just after 
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extracellular Na+ re-addition) and used to compare NHE-1 activity among different groups. The maximal 
intracellular acidification after the acidic load (measured just before Na+ re-addition) was of similar 
magnitude in both experimental groups.
At the end of each experiment, fluorescence emission was calibrated by exposing the muscles to a high-
KCl solution containing 10 µmol/L nigericin, a H+ -K+ exchanger that equals [H+]o to [H+]i when extracellular 
and intracellular K+ are the same. The calibration solution contained (in mmol/L) KCl 140.0, MgCl2 1.0, CaCl2 
1.35, HEPES 5.0, sodium cyanide 4, and BDM 20.0 to prevent muscle contracture. Buffer pH was adjusted 
with KOH or HCl to four different values ranging from 7.5 to 6.5. Such a calibration revealed a linear relation 
between pH and the fluorescence ratio (F495/F440) which was used to correct experimental ratios. All 
these ratios were calculated off-line after subtraction of the corresponding autofluorescence value at 
each wavelength as follows: (fluorescence at 495 nm-autofluorescence at 495 nm) / (fluorescence at 440 
nm-autofluorescence at 440 nm). All pharmacological interventions were started 20 minutes before the 
ammonium prepulse and kept for the entire protocol.
Western Blotting
Papillary muscles were homogenized in RIPA buffer (Santa Cruz Biotechnology, sc-24948) with 
protease inhibitors cocktail, PMSF and sodium orthovanadate. After a brief centrifugation the supernatant 
was kept and protein concentration determined by the Bradford method (Bio-Rad dye reagent) as described 
by the manufacturer with BSA as a standard. Samples were denatured and equal amounts of protein were 
subjected to PAGE and electrotransferred to PVDF membranes. Membranes were then blocked with non-fat 
dry milk (5 % in T-TBS) and incubated overnight with the specific antibodies against: phospho-ERK1 and 
ERK2, namely p-ERK1/2 (Santa Cruz Biotechnology, sc-16982), phospho-p90 RSK (Cell Signaling #9341), 
phospho-p38-MAPK (Millipore, MABS64), phospho-(Ser16)-Phospholamban (Bradilla, A010-12), phospho-
HSP27 (Santa Cruz Biotechnology, sc-166693) and DUSP6 (G-4) (Santa Cruz Biotechnology, sc-137246).
To determine NHE-1 phosphorylation at serine 703, the samples were immunoprecipitated using the 
NHE-1 polyclonal antibody and then subjected to PAGE, electrotransferred, blocked and incubated with 
anti-phospho-14-3-3 binding motif antibody (Cell Signaling, #9601) as previously described [14].
To normalize the amount of the phosphorylated proteins the membranes were stripped and probed 
with an antibody that detects GAPDH (Millipore, MAB374), NHE-1 (Santa Cruz Biotechnology, sc-28758) or 
Na+/K+-ATPase α (H-3) (Santa Cruz Biotechnology, sc-48345).
Peroxidase-conjugated anti-rabbit (NA934, GE Healthcare Life Sciences) and anti-mouse (NA931, GE 
Healthcare Life Sciences) were used as secondary antibodies and bands were visualized using the Immobilon 
Western chemiluminescent HRP substrate (Millipore, WBKLS0100). Autoradiograms were analyzed by 
densitometry (Scion Image).
RNA measurements by RT-PCR
Total RNA was isolated from the homogenized papillary muscles using the RNeasy kit (Qiagen, Valencia, 
CA, USA) according to the manufacturer’s instructions. RNA (0.8 μg) was reverse-transcribed using the 
Omniscript RT kit (Qiagen). A dilution of the resulting cDNA was used for quantifying the relative content 
of mRNA by real-time PCR (iCycler iQ Real-Time PCR Detection System, Bio-Rad) using appropriate primers 
and SYBR Green as a fluorescent probe. The following primers, designed using Primer3 software, were used: 
18S: forward primer 5-AGTCCCTGCCCTTTGTACAC-3; reverse primer 5-CCGAGGGCCTCACTAAACC-3; DUSP6: 
forward primer 5-CTGTGCCAAGGACTCTACTAAC-3; reverse primer 5-CAAACAGATTGGGCAGATTGG-3; 
DUSP7: forward primer 5-TCTCTCTCTCTCTCTCTCTCTCT -3; reverse primer 5-TGGCCACCCTCTGATATACT-3. 
PCR reactions were performed with TaqDNA polymerase (Invitrogen). Fluorescence data were acquired 
at the end of extension. A melt analysis was run for all of the products to determine the specificity of the 
amplification. The cycle threshold values for each gene were measured and calculated by computer software 
(iCycler IQ OSS, version 3.0a, Bio-Rad). The cycle threshold values for each gene were normalized by those 
of GAPDH in the same sample. For each experiment of real-time RT-PCR we obtained a melting curve of the 
amplified gene to confirm that only one product was amplified in each case with no primer-dimer formation.
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Chemicals
All drugs used in the present study were analytical reagent. SB202190 and SB202474 were 
respectively purchased from Sigma (Cat #S7067) and Santa Cruz Biotechnology (Cat #222290). The 10 
µmol/L concentration used in this study was selected based on previous reports [17, 18], and diluted in 
DMSO (final concentration 0.1 %).
Statistics
Data are expressed as mean ± SEM. One-way ANOVA followed by Student-Newman-Keuls test was used 
to compare data. A p value < 0.05 was considered statistically significant.
Results
SFR development and p38-MAPK inhibition
As an initial approach to identify whether p38-MAPK influences the SFR, the contractile 
response to stretch of isolated rat papillary muscles was compared in the absence and 
presence of the p38-MAPK inhibitor SB202190 (10 µmol/L) or its inactive analogous, 
SB202474 (10 µmol/L). The typical biphasic force response of a muscle suddenly stretched 
from 92 to 98 % of its maximal length is shown in Fig. 1A. The immediate increase in force is 
the expression of the well-known Frank–Starling mechanism, while the gradually developing 
one that follows, is the SFR. When the muscles were pre-incubated with the p38-MAPK 
inhibitor the SFR was significantly increased (Fig. 1B and 1D). Not significant changes in 
relaxation time were observed under p38-MAPK inhibition [time to half relaxation (msec), 
measured immediately and after 5 minutes of stretch, from 93±4 to 93±5, n=16 in control 
Stretch; and from 100±6 to 102±6, n=21 in Stretch+SB]. This finding indirectly suggests that 
myofilament responsiveness to calcium might not be responsible for the observed increase 
in force. Muscles pre-treated with the inactive analogous developed a SFR not different from 
untreated controls (Fig. 1C and 1D). Therefore, these results clearly indicate that p38-MAPK 
negatively regulates the SFR development.
p38-MAPK activation after stretch
In order to confirm that p38-MAPK is certainly activated by myocardial stretch, new 
experiments were performed in which papillary muscles were frozen 5 minutes after 
myocardial stretch and processed for phospho-p38-MAPK detection. We found a significant 
increase in p38-MAPK phosphorylation after stretch (Fig. 2A), effect that was precluded 
by pre-treatment with the p38-MAPK inhibitor (Fig. 2A). Moreover, to corroborate the 
activation of p38-MAPK after stretch, the phosphorylation level of HSP27, a well-known 
downstream target of p38-MAPK, was determined. Myocardial stretch induced a significant 
increase in HSP27 phosphorylation as depicted in Fig. 2B. Interestingly, muscles pre-treated 
with SB202190 did not show significant changes in HSP27 phosphorylation, while those 
pre-incubated with the inactive analogous SB202474 behaved like controls.
NHE-1 phosphorylation and activity
Since a phosphorylation-mediated increase in NHE-1 activity is a key factor in the chain 
of events leading to the SFR [19-23], we evaluated whether p38-MAPK inhibition had an 
effect upon this parameter. To this purpose, papillary muscles were frozen 5 minutes after 
myocardial stretch and processed for NHE-1 phosphorylation quantitation. As we have 
previously reported [14], myocardial stretch promoted a significant increase in NHE-1 
phosphorylation at serine 703 (Fig. 3A). Interestingly, this increase was even greater in the 
presence of SB202190 (Fig. 3A), suggesting that p38-MAPK was probably limiting ERK1/2-
p90RSK activation and therefore NHE-1 phosphorylation/activation.
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Since intracellular acidosis is the main stimulus for NHE-1 activation and previous 
studies by Zheng et al. [24] have reported acidosis-mediated-p38-MAPK activation, NHE-
1 activity was evaluated by comparing pHi recovery from an ammonium prepulse-induced 
acute acid load in the absence and presence of the p38-MAPK inhibitor SB202190 or its 
inactive analogous, SB202474. Interestingly, our results revealed a significant increase in the 
maximal NHE-1-mediated proton efflux after the acidic challenge in the presence of SB202190 
(Fig. 3B). In contrast, that effect was absent in muscles pre-treated with SB202474, the 
inactive analogous of SB202190 (Fig. 3B), confirming that p38-MAPK negatively regulates 
NHE-1 activity.
Fig. 1. SFR and p38-MAPK 
inhibition. A: Original force 
record from a rat papillary 
muscle stretched from 92 
to 98 % of Lmax showing 
the classical “two-phase” 
response. Individual traces 
corresponding to the points 
indicated in the upper 
panel with “a” (before 
stretch), “b” (immediately 
after stretch) and “c” (5 
minutes after stretch) 
are shown. B: Same as A, 
but from a muscle pre-
incubated with the p38-
MAPK inhibitor, SB202190 
(“St+SB”), where it can be 
appreciated a greater SFR. 
C: same as A, but from a 
muscle pre-incubated with 
the SB202190 inactive 
analogous, SB202474 
(“St+IA”). D: Averaged 
results after 5 minutes 
of stretch under all 
experimental conditions, 
expressed as a percentage 
of the initial rapid phase. 
Inset: The original force 
record shown in panel “A” 
was used to identify the 
characteristic two phases 
increase in force following 
myocardial stretch, as 
well as the calculation 
used to express the SFR 
in percentage form: 
“1” indicates the initial 
rapid phase generated 
immediately after stretch 
and considered as 100 %; 
“2” highlights the SFR observed at 5 minutes of stretch. The final magnitude of the SFR was calculated as (2 
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Crosstalk between p38-MAPK and ERK1/2-p90RSK after myocardial stretch
Considering that ERK1/2 and p90RSK lead to NHE-1 activation during the SFR [14, 25], 
we explore the effect of p38-MAPK inhibition on the phosphorylation state of these kinases 
after stretch. Fig. 4 shows that myocardial stretch induced a greater increase in ERK1/2 and 
p90RSK phosphorylation when p38-MAPK was inhibited, consistent with the increase in 
NHE-1 phosphorylation described before (Fig. 3A). ERK1/2 and p90RSK phosphorylation 
level in muscles pre-treated with SB202474 was similar to that observed in untreated 
controls (Fig. 4). These results support the notion of a counterbalancing effect of p38-MAPK 
and ERK1/2 - p90RSK on NHE-1 phosphorylation during myocardial stretch.
Phospholamban phosphorylation after stretch
As we already mentioned, it has been reported that pharmacological inhibition of 
p38-MAPK strengthens the positive inotropic effect induced by ET-1 in isolated perfused 
rat hearts by increasing PLN phosphorylation at serine 16 [10]. Since ET is involved in 
the signaling pathway triggered by myocardial stretch (for review see [1]), we thought to 
explore whether this mechanism contributes to the bigger SFR observed under p38-MAPK 
inhibition. In contrast to this possibility, PLN phosphorylation at serine 16 was unaffected 
by myocardial stretch either in the absence or presence of SB202190 (Fig. 5), excluding its 
participation in the SFR.
Up-regulation of DUSP6 after myocardial stretch
To get further insight into the mechanism underlying the increase in the stretch-
induced phosphorylation of ERK1/2, p90RSK and NHE-1 under p38-MAPK inhibition, we 
explored the putative involvement of DUSP6 and DUSP7, dual phosphatases that specifically 
dephosphorylates cytosolic ERK1/2 [26]. Fig. 6A shows a significant increase in DUSP6 mRNA 
abundance after 5 min of stretch, effect that was prevented by SB202190. In agreement, five 
Fig. 2. p38-MAPK activation after myocardial stretch. A: Stretch (“St”) significantly increased p38-MAPK 
phosphorylation (p-p38-MAPK) compared to the non-stretched control (“C”). As it can be appreciated, this 
effect was cancelled when the muscles were pre-treated with the p38-MAPK inhibitor SB202190 (“St+SB”), 
but not by SB202474, the inactive analogous of SB202190 (“St+IA”). B: Five minutes of stretch significantly 
increased HSP27 phosphorylation, a known downstream target of p38-MAPK. This effect was blunted by 
the p38-MAPK inhibitor (“St+SB”), but not by the inactive analogous (“St+IA”), demonstrating that p38-
MAPK is activated by the stretch. Bar graphs depict averaged data. Representative blots are shown on top 
of the bars. Importantly, neither SB202190 nor its inactive analogous (SB202474) alone modified basal 
p-p38-MAPK (105±4 % of control, n=6 and 102±4% of control, n=4, respectively) or p-HSP27 (88±6% of 
control, n=4 and 98.5±12% of control, n=4). * indicates p<0.05 vs control (non-stretched) and # indicates 
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Fig. 4. ERK1/2 and p90RSK phosphorylation after stretch. As reported previously [25], myocardial stretch 
(St) significantly increased ERK1/2 (A) and p90RSK (B) phosphorylation compared to non-stretched 
controls (“Control” or “C”). In the presence of the p38-MAPK inhibitor SB202190 (“SB”), myocardial stretch 
promoted a greater increase in ERK1/2 and p90RSK phosphorylation, effect that was not observed in 
muscles pre-treated with the inactive analogous SB202474 (“St+IA”). SB and IA alone did not modify the 
phosphorylation of either ERK1/2 (90±9 % of control, n=5 and 97 ±6 % of control, n=5, respectively) or 
p90RSK (105±4 % of control, n=5 and 93±8 % of control, n=4, respectively). * indicates p<0.05 vs. control, 





















Fig. 3. NHE-1 activation. A: In agreement 
with what we have shown previously 
[14], NHE-1 phosphorylation at serine 
703 (estimated by a phospho-Ser 14-3-3 
binding motif antibody, “p-14-3-3-BM”) 
was significantly increased by myocardial 
stretch (“St”) compared to non-stretched 
controls (“Control”), as shown in the original 
western blots (top) and the averaged data 
(bottom). Interestingly, this effect was 
magnified in stretched muscles pre-treated 
with the p38-MAPK inhibitor, SB202190 
(“St+SB”). SB alone did not modify basal 
NHE-1 phosphorylation (92±6 % of control, 
n=3). B: Consistently, p38-MAPK inhibition 
(“SB”) significantly increased NHE-1-
mediated H+ efflux (JH+) after an acidic 
challenge (ammonium prepulse), effect that 
was not observed in muscles pre-treated 
with the inactive analogous of SB202190, 
SB202474 (IA). Typical pHi recordings (top) 
and averaged initial (maximal) H+ efflux 
(bottom) under all experimental conditions 
are shown. For the sake of comparison, the 
best exponential fit for each pHi recovery 
from acidosis was superimposed. * 
indicates p<0.05 vs non-stretched Control, 
** indicates p<0.05 vs. St, and # indicates 
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minutes of myocardial stretch promoted a significant 
increase in the protein expression of DUSP6, compared 
to non-stretched controls, effect that was abrogated 
by the p38-MAPK inhibitor SB202190 (Fig. 6B). These 
results suggest that p38-MAPK activation by stretch 
induces the up-regulation of DUSP6. In contrast, 
DUSP7 appears not to be involved in the mechanism 
triggered by myocardial stretch as shown in Fig. 6C. It 
is important to keep in mind that the activity of these 
phosphatases depends on its level of expression [26-
28].
Discussion
Our current data provide strong evidence to include 
the activation of p38-MAPK and DUSP6 as novel steps 
in the complex mechanism triggered by myocardial 
stretch and leading to the SFR. The major findings of 
our study are that p38-MAPK inhibition strengthens 
the stretch-stimulated ERK1/2-p90RSK and NHE-
1 phosphorylation and activities, consequently 
promoting a greater SFR. We propose that cardiac 
stretch promotes a p38-MAPK-mediated increase in 
DUSP6 activity, restricting ERK1/2-p90RSK and NHE-
1 phosphorylation/activation and therefore limiting 
the SFR development. Conversely, under p38-MAPK inhibition the prevention of DUSP6 up-
regulation would allow a larger increase in ERK1/2 phosphorylation, which determines a 
greater activity of p90RSK and NHE-1, leading to a bigger SFR.
Fig. 5. Phospholamban phosphorylation after stretch. 
Phospholamban (PLN) phosphorylation at serine 16 was 
unaffected by myocardial stretch either in the absence (“St”) 
or presence (“St+SB”) of SB202190 compared to non-stretched 
controls (“C”). Representative blots (top) and averaged data 
(bottom) under all experimental conditions are shown. 
PLN phosphorylation was expressed as % of its maximal 
phosphorylation state induced by 100 nmol/L isoproterenol 

















Fig. 6. Up-regulation of DUSP6 after myocardial stretch. Five 
minutes of myocardial stretch (“St”) promotes a significant increase 
in mRNA (A) and protein (B) expression of DUSP6, compared 
to non-stretched controls (“C”), effects that were precluded by 
the p38-MAPK inhibitor SB202190 (“St+SB”). In contrast, not 
significant changes in DUSP7 mRNA expression was found either 
in the absence or presence of SB202190 (C).* indicates p<0.05 vs. 
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Previous reports by Liao et al. [5] and by Kockskamper et al. [29] support the notion 
that p38-MAPK activation negatively regulates cardiac contractility by decreasing 
myofilament Ca2+ responsiveness. The latter study is of particular interest for us since the 
authors described a greater SFR to stretch in human trabeculae when the activation of 
p38-MAPK was prevented by SB203580, a different inhibitor from the one used herein. 
Furthermore, they also described an increase in basal developed force after p38-MAPK 
inhibition, suggesting that this kinase regulates cardiac contractility not only after stretch 
but also under basal conditions. Although the authors stated that the precise mechanism 
underlying these effects was still unknown, the fact that the positive inotropic effect detected 
after p38-MAPK inhibition was associated with a prolonged relaxation time, leaded them 
to tentatively assign a role to increased myofilament Ca2+ sensitivity as mentioned above. 
However, our current results do not appear to support their findings. In fact, the finding of 
an increased NHE-1 phosphorylation/activity under p38-MAPK inhibition (Fig. 3) allows us 
to suggest that a greater increase in intracellular Ca2+, as a consequence of NHE-1-dependent 
intracellular Na+ overload, would be the main responsible for the larger SFR detected under 
these experimental conditions. Furthermore, although our data do not allow to completely 
exclude changes in myofilament Ca2+ responsiveness contributing to the increase in SFR, the 
absence of changes in the relaxation time during the SFR appears to reject this possibility. 
On the other hand, the fact that p38-MAPK inhibition failed to alter baseline contractility, 
suggests that p38-MAPK does not regulate basal contractility in rat papillary muscles.
The most relevant group of protein phosphatases in mammalian cells that specifically 
regulates MAPKs activity is the dual specificity MAPK phosphatases, (MKPs or DUSPs) [30]. 
The main characteristic of several DUSPs is their regulation at the level of gene expression 
following stress or mitogen stimulation, providing a negative feedback to limit the extent and 
duration of MAPK signaling [26-28]. Once expressed, the DUSPs are constitutively active and 
capable of directly binding to the activation loop in MAPKs, resulting in dephosphorylation. 
Each DUSPs differs with respect to the subcellular localization, tissue expression, or specificity 
for each MAPK [26-28]. DUSP6 is a member of the large family of MAPK phosphatases that 
bind with varying specificity to ERK1/2, JNK1/2, p38-MAPK, ERK5, and presumably ERK3/4 
[26, 27]. DUSP6 is known to form a complex with ERK2 through a series of amino acids that are 
conserved in ERK1, but not ERK5 or ERK3/4, suggesting that it is highly specific for ERK1/2. 
In Dusp6-/-mice, Maillet et al. [31] showed an increase in basal ERK1/2 phosphorylation in 
several tissues, but no change in ERK5, p38-MAPK, or c-Jun N-terminal kinases activation. 
Even more importantly, Purcell et al. [32] generated transgenic mice overexpressing DUSP6 
in the heart and showed a complete absence of ERK1/2 phosphorylation at baseline or 
after any applied stress stimulus; nevertheless ERK5, p38-MAPK, and JNK phosphorylation 
were unaffected [32]. Although the experimental evidence indicates that DUSP6 only affects 
ERK1/2 within the greater MAPK family, we cannot rule out the possibility that it could affect 
other proteins implicated in the SFR development.
In the present study, we did not explore the mechanism by which myocardial stretch 
up-regulates DUSP6. It has been described that DUSP6 expression is induced in response to 
elevated ERK1/2 signalling as a feedback regulator [33]. Our current results do not appear 
to support this concept since when the stretch was performed under p38-MAPK inhibition 
(Fig. 4) we observed a greater increase in ERK1/2 without changes in DUSP6 expression, 
which was similar to that in non-stretched muscles (Fig. 6A). Therefore, our data strongly 
suggests a p38-MAPK-mediated increase in DUSP6 expression after myocardial stretch.
Modulation of ERK1/2 activity by p38-MAPK has been previously described in different 
tissues [11, 34]. Furthermore, it has been shown that specific activation of p38-MAPK by 
overexpression of a constitutively active MAPK kinase-3b inhibits ERK1/2 [35]. Our result 
showing p38-MAPK-dependent inhibition of ERK1/2 phosphorylation following myocardial 
stretch is consistent with these findings.
A previous work reported the direct phosphorylation of NHE-1 between amino acids 625 
and 747 by p38-MAPK [11]. The authors speculated that this phosphorylation might either 
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induce a conformational change that inhibits transport activity, or prevent the interaction 
with other regulatory molecules crucial for transport activity. Herein, we measured NHE-
1 phosphorylation at the residue serine 703, a documented p90RSK target that does not 
appear to be phosphorylated by p38-MAPK [12], detecting an increased phosphorylation of 
this site when myocardial stretch was performed under p38-MAPK inhibition.
Finally, in isolated perfused rat hearts, Ruskoaho et al. [10] were able to show that the 
positive inotropic effect of ET-1, a known mediator of the SFR to stretch, can be diminished 
by pharmacological inhibition of the NHE-1. Interestingly, they also showed that the increase 
in force could be potentiated by p38-MAPK inhibition, being the positive inotropic effect 
due to enhanced SERCA2a activity as consequence of increased PLN phosphorylation [10]. 
Despite the differences in the experimental conditions, as well as the potent vasoconstrictor 
effect of ET-1 in the perfused heart, the demonstrated crucial role of NHE-1 activation in 
the peptide-triggered positive inotropic response is in line with previous findings of our 
group in isolated papillary muscles [21, 36]. However, we were not able to detect significant 
changes in PLN phosphorylation following myocardial stretch under p38-MAPK inhibition 
(Fig. 5), reinforcing the notion that the sarcoplasmic reticulum does not participate in the 
development of the SFR, as reported by others [37-39].
Conclusion
In conclusion, the present study demonstrates that p38-MAPK activation after stretch 
negatively regulates the SFR. The proposed underlying mechanism is that myocardial stretch 
activates p38-MAPK up-regulating DUSP6 that in turn limits ERK1/2-p90RSK and NHE-1 
phosphorylation/activation. A schematic representation of the proposed mechanism is 
depicted in Fig. 7.
Fig. 7. Schematic representation of the proposed mechanism, based on our current and previous findings. 
Under control conditions (A), myocardial stretch triggers p38-MAPK activation and DUSP6 up-regulation, 
therefore restricting the increase in ERK1/2-p90RSK and NHE-1 phosphorylation/activation [14, 25], with 
the consequent limitation of the SFR amplitude. Prevention of p38-MAPK activation (B) precludes DUSP6 
up-regulation after stretch allowing a higher phosphorylation of ERK1/2-p90RSK and consequently of NHE-
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